Abivax S.A. ABVX · Stock Open Abivax S.A. in new tab
Abivax S.A. Analysis (ABVX)
Is Abivax S.A. a good investment? Abivax S.A. (ABVX) is currently trading at 144.65 USD. Market analysts have a consensus price target of 150.73 USD. This suggests a potential upside from current levels.
Earnings Schedule: Abivax S.A. is expected to release its next earnings report on Sept. 14, 2026. The market consensus estimate for Forward EPS is -3.27.
Investor FAQ
Does Abivax S.A. pay a dividend?
No, it does not currently pay a dividend.
What asset class is Abivax S.A.?
Abivax S.A. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be Sept. 14, 2026. The company currently has a trailing EPS of -5.25.
Company Profile
ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod, which is in Phase 3 clinical development for the treatment of moderately to severely active UC, as well as Phase 2b clinical trials for Crohn's disease. The company was incorporated in 2013 and is headquartered in Paris, France.
Community Discussion